A compound of Formula I, Formula IA, Formula IB, or Formula II, or an acid or base addition salt thereof, and use of these compounds as antioxidants. In one embodiment, a compound of Formula II, ##STR00001##
wherein each of X, Y, and Z are independently a carbon or nitrogen atom; R.sup.1 and R.sup.2 are each independently a hydrogen or an electron donating group, but are not both hydrogen, and wherein R.sup.1, and R.sup.2 are each bonded to a carbon atom in their own respective aryl ring.

A compound of Formula I, Formula IA, Formula IB, or Formula II, or an acid or base addition salt thereof, and use of these compounds as antioxidants. In one embodiment, a compound of Formula II, ##STR00001##
wherein each of X, Y, and Z are independently a carbon or nitrogen atom; R.sup.1 and R.sup.2 are each independently a hydrogen or an electron donating group, but are not both hydrogen, and wherein R.sup.1, and R.sup.2 are each bonded to a carbon atom in their own respective aryl ring.

The present invention is directed to particle comprising a supramolecular complex comprising a monofunctional and/or a bifunctional subunit comprising a quadruple hydrogen bonding unit, an apolar linker, an urea group, and a polyethyleneglycol linker. The monofunctional subunits comprise a functional group. The particles are very suitable as drug delivery system as they bind and enter the cell and may have slow release properties.

The present invention is directed to particle comprising a supramolecular complex comprising a monofunctional and/or a bifunctional subunit comprising a quadruple hydrogen bonding unit, an apolar linker, an urea group, and a polyethyleneglycol linker. The monofunctional subunits comprise a functional group. The particles are very suitable as drug delivery system as they bind and enter the cell and may have slow release properties.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Described herein are cyclopentyl nucleoside analogs of Formula (I), pharmaceutical compositions that include one or more cyclopentyl nucleoside analogs and methods of using the same to treat HBV, HDV and/or HIV. (I)

##STR00001##

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R.sub.1, L and R.sub.2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. ##STR00001##

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R.sub.1, L and R.sub.2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. ##STR00001##

The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof:

##STR00001##

wherein the variable groups X, R.sup.1, R.sup.2, R.sup.3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.